Table I.

Demographics of Subjects Stratified by Sputum %Eos+%Neu. Results from ANOVA are presented as mean+SEM; results from Kruskal-Wallis analysis of variance are presented as median (25%–75%), p values meeting Bonferroni correction are in bold font:

Categories:		<2%Eos <40%Neu	<2%Eos ≥40%Neu	≥2%Eos <40%Neu	≥2%Eos ≥40%Neu	P value
N=175		63 (36%)	50 (29%)	42 (24%)	20 (11%)
Gender	%Female	81%	76%	74%	60%	0.30
Age (yr)		33±1.6	42±1.9	34±1.8	40±2.1	<0.001
Age Onset		10 (4–24)	13 (5–26)	13.5 (2–23)	7.5 (3–30)	0.92
Duration		17±1.6	25±2.1	19±1.9	23±2.5	0.014
Lung Function:	Baseline FEV1 % Predict.	86.5±2.0	80.4±2.3	76.6±2.8	66.6±4	<0.001
	Baseline FVC% Predict.	93.8±1.8	87.0±2.0	90.5±2.7	81.7±3.7	0.01
	FEV/FVC	0.77±0.01	0.75±0.01	0.70±0.02	0.66±0.03	<0.001
	Max FEV1% Predict.	95.4±1.8	88.8±1.9	90.3±2.6	80.8±4.2	0.003
	%Rev 2puff β agonist	9.89±10	7.98±5.8	14.5±12.3	15.8±15.5	0.005
	Change FEV1%pred (max-baseline)	9.1±6.5	8.3±6.4	13.7±10.3	14.7±10.1	0.002
	LogPC20*	0.47±0.1 N=55	0.41±0.1 N=46	−0.013±0.1 N=34	;0.23±0.3 N=14	0.006
	FeNO	22.9±1.1	20.0±1.1	49.0±1.1	30.9±1.2	<0.001
	Freq + skin test	83%	78%	86%	89%	0.66
	No. + skin tests	4 (2–6.8)	3 (1–5.3)	4 (2–7.3)	4 (2–7)	0.59
	Serum eos	0.20 (0.1–3.3)	0.20 (0.1–2.5)	0.30 (0.2–2.5)	0.30 (0.2–2.1)	0.001
	IgE	126±1.2	78±1.3	191±1.3	100±1.3	0.06
Asthma Control & Healthcare Utilization†:	daily use β-agonist	24%	28%	60%	55%	<0.001
	Ever ER visits	57%	70%	69%	80%	0.21
	>1 urgent HC visit in past year	22%	40%	19%	70%	<0.001
	Symptoms worse if reduce CS	49%	39%	38%	70%	0.07
	>3 oral CS bursts/yr	17%	12%	9%	30%	0.17
	Ever spent night in Hospital	25%	40%	38%	40%	0.07
	Ever ICU admitted	6%	8%	21%	25%	0.009
Symptoms†:	>daily wheeze	13%	14%	26%	50%	0.002

^*Not all subjects met safety criteria for methacholine challenge.

^†% of category answering “yes”